LL-37

Quick Summary

• What it is: LL-37 is the only human cathelicidin-derived antimicrobial peptide (AMP), produced primarily by epithelial cells, neutrophils, and keratinocytes as part of the innate immune system.
• Regulatory status: Removed from FDA Category 2 on April 15, 2026. LL-37 was not among the seven peptides the Pharmacy Compounding Advisory Committee reviewed in July 2026, and no PCAC review is currently scheduled for it. Currently available through licensed 503A compounding pharmacies with valid prescription.
• Research stage: Preclinical and early clinical. LL-37 has been studied in wound healing, antimicrobial applications, and immune modulation, with approximately 2,500 PubMed-indexed publications as of May 2026.
• Key distinction: Unlike BPC-157 or TB-500 (synthetic analogues), LL-37 is an endogenous human peptide — the body produces it naturally — which gives it a different safety profile in terms of immunogenicity.

What Is LL-37?

LL-37 is a 37-amino acid amphipathic alpha-helical peptide encoded by the CAMP (cathelicidin antimicrobial peptide) gene. It is the only member of the cathelicidin family of antimicrobial peptides expressed in humans (other mammals have multiple cathelicidins). The peptide is generated by proteolytic cleavage of the hCAP-18 precursor protein.

LL-37 serves multiple functions in the innate immune system:

• Direct antimicrobial activity: Disrupts bacterial, fungal, and enveloped viral membranes through electrostatic interaction with negatively charged microbial lipid bilayers.
• Immune modulation: Chemoattracts neutrophils, monocytes, and T-cells; modulates dendritic cell differentiation; suppresses pro-inflammatory cytokine release under certain conditions.
• Wound healing: Promotes re-epithelialization, angiogenesis, and fibroblast migration at wound sites.
• Biofilm disruption: Shown to inhibit and disrupt bacterial biofilms at sub-antimicrobial concentrations, a property of interest for chronic wound and implant-associated infections.

Research Overview

Antimicrobial Activity

LL-37 exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. A 2024 systematic review in Frontiers in Microbiology found LL-37 effective against MRSA, Pseudomonas aeruginosa, and Acinetobacter baumannii at micromolar concentrations. The peptide’s mechanism — membrane disruption rather than receptor-specific inhibition — makes conventional resistance development less likely.

A May 2026 Europe PMC-indexed study examined molecular interaction modes of LL-37 and its mutants, identifying structural determinants of antimicrobial activity that could inform synthetic analogue design.

Wound Healing

The cathelicidin peptide LL-37 plays a central role in cutaneous wound repair. It stimulates keratinocyte migration and proliferation through transactivation of the epidermal growth factor receptor (EGFR). A March 2026 study in Frontiers in Pharmacology explored the role of LL-37 and ceragenins (synthetic cationic steroid antibiotics) in wound healing processes, reporting improved re-epithelialization rates in ex vivo human skin models.

Clinical interest focuses on chronic wounds (diabetic ulcers, venous stasis ulcers) where endogenous LL-37 levels are often suppressed by the inflammatory microenvironment. Topical LL-37 formulations have been explored as a therapeutic strategy to restore healing capacity in these settings.

Cancer Biology

LL-37 has a dual role in cancer biology that complicates its therapeutic profile. A December 2025 study found increased cathelicidin LL-37 colonic expression associated with tumor progression in colorectal cancer. Conversely, the peptide has been shown to exhibit anti-tumor activity against certain cancer cell lines through membrane disruption and immune activation.

A March 2026 study examined LL-37’s role in cancer cell migration control, highlighting the context-dependent nature of its effects. This dual activity — pro- and anti-tumorigenic depending on tissue microenvironment — is an active area of investigation.

Neutrophil Extracellular Traps

May 2026 research demonstrated that LL-37 compacts nucleic acids and alters neutrophil extracellular trap (NET) structure. This finding has implications for both innate immune function and autoimmune conditions where NET dysregulation is implicated, such as systemic lupus erythematosus and rheumatoid arthritis.

Regulatory Status

Pre-April 2026

LL-37 was included in the FDA’s April 2023 enforcement action placing 14 peptides in Category 2 (significant safety concern), effectively prohibiting compounding pharmacies from bulk production. The FDA cited: (1) lack of FDA-approved drug products containing LL-37, (2) insufficient published evidence of safety and efficacy for clinical use, and (3) concerns about unregulated distribution through research chemical suppliers.

April 15, 2026 Reclassification

The FDA removed LL-37 from Category 2 along with 11 other peptides (GHK-Cu was already in Category 1). This reclassification, announced during the agency’s response to an industry citizen petition, allows 503A compounding pharmacies to produce LL-37 under valid patient-specific prescriptions. The FDA stated the action was based on a “refined evaluation of the scientific evidence and public health considerations.”

LL-37 and the July 2026 PCAC meeting

LL-37 was not on the agenda for the Pharmacy Compounding Advisory Committee’s July 23–24, 2026 meeting. That docket covered seven other peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon — and PCAC recommended six of them for the 503A Bulks List. LL-37 was not reviewed, and no PCAC review of it is currently scheduled. The 503A Bulks List is the permanent framework for compounding ingredients not otherwise included in FDA-approved drug products, so LL-37’s placement remains unresolved rather than decided against.

Placement scenarios

Because LL-37 was not reviewed in July 2026, both outcomes below remain open, and no review date is scheduled:

• Placed on 503A Bulks List: LL-37 becomes a permanently available compounding ingredient under the standard 503A framework. Compounding pharmacies may produce it indefinitely under valid prescriptions.
• Not placed on Bulks List: compounding access would narrow to the enforcement-discretion posture that has applied since April 15, 2026, with the FDA signalling it would treat bulk LL-37 as a safety concern for compounded use. Access for individual patients would depend on documented medical need and the agency’s enforcement priorities.

Safety Profile

LL-37’s status as an endogenous human peptide provides a theoretical safety advantage over synthetic analogues — the human immune system is unlikely to mount an adaptive immune response against a self-peptide. However, several safety considerations warrant attention:

• Pro-inflammatory effects at high concentrations: LL-37 can trigger mast cell degranulation and enhance endotoxin-mediated inflammation at supraphysiological doses.
• Cytotoxicity at high doses: Like all antimicrobial peptides, LL-37 exhibits concentration-dependent cytotoxicity against mammalian cells, though the therapeutic index appears favorable in preclinical models.
• Cancer context-dependence: As noted above, LL-37’s role in cancer progression is tissue-dependent. Patients with active malignancies or cancer risk factors should be evaluated cautiously.
• Limited human clinical data: No FDA-approved LL-37 drug product exists. Human data come from small observational studies and case reports, primarily in wound healing contexts.

Key Differences from Other Reclassified Peptides

Feature	LL-37	BPC-157	TB-500
Origin	Endogenous human	Synthetic (based on body protein)	Synthetic (thymosin beta-4 fragment)
Primary mechanism	Antimicrobial + immune modulation	Angiogenesis + GI healing	Actin binding + cell migration
Research volume	~2,500 papers	~1,200 papers	~800 papers
Human clinical data	Limited (topical wound studies)	Minimal	Minimal
Cancer signal	Dual (pro/anti-tumorigenic)	Mixed	Mixed

Bottom Line

LL-37 holds a unique position among the reclassified peptides: as the only endogenous human antimicrobial peptide on the list, its scientific foundation is distinct from the synthetic analogues. That distinction has not yet been tested at a PCAC review, because LL-37 was not among the seven peptides the committee reviewed in July 2026 — so whether the FDA accepts that LL-37’s clinical evidence base supports permanent compounding access remains an open question rather than a settled one.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.